{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-051567","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.402011+00:00","generated_at":"2026-05-19T22:50:08.509981+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Apimeds Pharmaceuticals appoints Erick J. Frim as CFO, replacing Mark Corrao","bullets":["Erick J. Frim, 67, appointed CFO effective May 30, 2025, succeeding Mark Corrao.","Mr. Frim has over 40 years of financial management experience, most recently as interim CFO of Helio Corporation.","Compensation: $2,500 per month for first 8 hours, $250 per hour thereafter under a one-year consulting agreement.","No familial relationships or reportable related-party transactions with the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-051567","json":"https://secwatch.observer/filing/0001213900-25-051567.json","markdown":"https://secwatch.observer/filing/0001213900-25-051567.md","text":"https://secwatch.observer/filing/0001213900-25-051567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/ea024484201-8k_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T22:50:08.509981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdb9334875","claim":"Mark Corrao departed as Chief Financial Officer at Apimeds Pharmaceuticals US, Inc..","evidence_excerpt":"On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e5cb12b209","claim":"Erick J. Frim was appointed as Chief Financial Officer at Apimeds Pharmaceuticals US, Inc..","evidence_excerpt":"On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}